国产替罗非班在急性冠状动脉综合征中的应用被引量：1

导出

摘要目的观察国产替罗非班治疗急性冠状动脉综合征（ACS）的临床效果和安全性。方法将50例急性冠状动脉综合征患者，随机分为治疗组26例，对照组24例。对照组给予阿司匹林波立维0．3g嚼碎顿服，低分子肝素（立迈青针）5000U，腹壁皮下注射，每12小时1次，共7d，阿司匹林0．1mg晨服，波立维75mg晨服，辛伐他汀、倍他乐克、硝酸甘油等治疗；治疗组在此基础上应用盐酸替罗非班氯化钠注射液，前30min以0．4μg／（kg·min）负荷输入，后以0．1μg／（kg·min）静脉泵输入维持24h；观察两组疗效。结果24h及30d的终点事件发生率，治疗组低于对照组（P〈0．01），出血并发症两组比较差异无统计学意义（P〉0．05）。结论在低分子肝素基础上加用替罗非班治疗急性冠状动脉综合征，不增加严重出血的发生率，安全性较好。

作者韩丽萍

机构地区河南省鄢陵县人民医院内二科

出处《中国实用医刊》 2012年第13期122-123,共2页 Chinese Journal of Practical Medicine

关键词急性冠状动脉综合征替罗非班

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献4

1李琳,洪江.非ST段抬高急性冠脉综合征的抗栓治疗进展[J].临床药物治疗杂志,2010,8(2):17-22. 被引量：1
2高爱玲,张素清,乔亚京,逯保军,韩雪梅,陈旭红.盐酸替罗非班治疗急性冠状动脉综合征的安全性和有效性评价[J].中国实用医刊,2009,36(2):58-59. 被引量：1
3吕树铮.非ST段抬高急性冠脉综合征优化治疗策略[J].中国心血管病研究,2009,7(9):641-642. 被引量：7
4彭长农,胡雪松,方卫华,衣为民,刘幼文,刘强,龙娟,李忠红,金光临.非ST段抬高急性冠脉综合征的早期介入治疗研究[J].中国基层医药,2004,11(7):777-778. 被引量：2

二级参考文献25

1Antithrombotic Trialists'Collaboration. Collaborative Metaanalysis of randomized trials of antiplateiet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [ J ]. BMJ, 2002, 324(7329) : 71-86. 被引量：1
2Yusuf S, Zhao F, Mehta SR,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST - segment elevation[J]. N Engl J Med,2002, 345(7) : 494-502. 被引量：1
3Steinhubl SR, Berger PB, Mann JT Ⅲ, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention : a randomized controlled trial[ J]. JAMA ,2002, 288 ( 19 ) : 2411 - 2420. 被引量：1
4Rioufo G, Gilard M, Finet G, et al. Evolution of spontaneous atherosclerotic plaque rupture with medical therapy : Long - term follow - up with intravascular ultrasound [ J ]. Circulation. 2004, 110 (18) :2875-2880. 被引量：1
5Mehta SR, Yusuf S, Peters R J, et al. Effects of pretreatment with clopidogrel undergoing study [ J ]. and aspirin followed by long - term therapy in patients percutaneous coronary intervention: the PCI - CURE Lancet ,2001, 358 ( 9281 ) : 527- 533. 被引量：1
6Wiviott SD, Antman EM, Winters K J, et al. JUMBO- TIMI 26 Investigators: Randomized comparison of prasugrel ( CS - 747, LY640315), a novel thienopyridine P2YI2 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint U- tilization of Medications to Block Platelets Optimally (JUMBO) - TIMI 26 trial[ J]. Circulation. 2005,111 (25) :3366- 3373. 被引量：1
7Kastrati A, Mehilli J, Sch"uhlen H, et al. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel[J]. N Engl J Med,2004, 350(3): 232-238. 被引量：1
8Kastrati A, Mehilli J, Neumann FJ, et al. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 ( ISAR - REACT 2 ) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR - RE- ACT2 randomized trial[J]. JAMA,2006, 295( 13): 1531- 1538. 被引量：1
9Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high posttreatment platelet aggregation in patients undergoing coronary stenting[J]. J Am Coil Cardiol,2005,45(9) : 1392-1396. 被引量：1
10Dalby M, Montalescot G, dit Sollier CB, et al. Eptifibatide provides additional platelet inhibition in non - ST - elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non - Q - wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study[J]. J Am Coll Cardiol,2004, 43(2) : 162- 168. 被引量：1